Reports Q4 revenue $167.33M, consensus $180.37M. "In 2022, we continued to execute on our long-term growth strategy focusing on successfully transitioning from our legacy and mature products to our growth products, and finished the year with record revenues of $667.2M, up 15% from the prior year," said CEO Jack Khattar. "Based on this successful transition and with a solid foundation, we are confident that our growth drivers will allow us to offset the impact coming from loss of exclusivity for Trokendi XR and position us well to drive strong revenue and non-GAAP operating income growth in 2024 and beyond."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on SUPN:
- Supernus to Present at the Cowen 43rd Annual Health Care Conference
- Supernus Announces Fourth Quarter and Full Year 2022 Financial Results
- Supernus Enters Into $150 Million Credit Facility
- Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 28, 2023
- Supernus price target raised to $47 from $40 at Piper Sandler
